Silexion Therapeutics Ltd.
Support and Resistance Levels
Past performance
News About SLXN
All events for SLXN
All deals for SLXN
Financial Ratios
Financial Statements
SLXN vs Sector & Peers
About Silexion Therapeutics Ltd.
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel. Website silexion.com
Headquarters Jerusalem, IL